NO20076390L - Compositions and methods for the treatment of malaria with cupredoxin and cytochrome - Google Patents

Compositions and methods for the treatment of malaria with cupredoxin and cytochrome

Info

Publication number
NO20076390L
NO20076390L NO20076390A NO20076390A NO20076390L NO 20076390 L NO20076390 L NO 20076390L NO 20076390 A NO20076390 A NO 20076390A NO 20076390 A NO20076390 A NO 20076390A NO 20076390 L NO20076390 L NO 20076390L
Authority
NO
Norway
Prior art keywords
cytochrome
malaria
cupredoxin
compositions
malaria infection
Prior art date
Application number
NO20076390A
Other languages
Norwegian (no)
Inventor
Ananda Chakrabarty
Tapas Das Gupta
Tohru Yamada
Arsenio Fialho
Anita Chaudhari
Chang Soo Hong
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of NO20076390L publication Critical patent/NO20076390L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Den foreliggende oppfinnelsen er relatert til cupredoxin og cytokrom og deres anvendelse, separat eller sammen, for å inhibere spredningen av parasitemi i mammalske, røde blodceller og andre vev infiserte ved malariaparasitten og spesielt parasitemien av humane, røde blodceller ved P. falciparum. Oppfinnelsen tilveiebringer isolerte peptider som er varianter, derivater eller strukturelle ekvivalenter av cupredoxiner og cytokrom c og sammensetninger omfattende cupredoxiner og/eller cytokrom c, eller varianter, derivater eller strukturelle ekvivalenter derav, som er nyttige for behandling eller forebygging av malariainfeksjon i pattedyr. Videre tilveiebringer oppfinnelsen fremgangsmåter for å behandle mammalske pasienter for å forebygge eller inhibere veksten av malariainfeksjon i pattedyr. Oppfinnelsen tilveiebringer også fremgangsmåter for å forebygge veksten av malariainfeksjon i insektsvektorer.The present invention relates to cupredoxin and cytochrome and their use, separately or together, to inhibit the spread of parasitemia in mammalian red blood cells and other tissues infected by the malaria parasite and in particular the parasitemia of human red blood cells by P. falciparum. The invention provides isolated peptides which are variants, derivatives or structural equivalents of cupredoxins and cytochrome c and compositions comprising cupredoxins and / or cytochrome c, or variants, derivatives or structural equivalents thereof, useful for treating or preventing malaria infection in mammals. Furthermore, the invention provides methods for treating mammalian patients to prevent or inhibit the growth of mammary malaria infection. The invention also provides methods for preventing the growth of malaria infection in insect vectors.

NO20076390A 2005-05-20 2007-12-11 Compositions and methods for the treatment of malaria with cupredoxin and cytochrome NO20076390L (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68281305P 2005-05-20 2005-05-20
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US78086806P 2006-03-10 2006-03-10
PCT/US2006/019492 WO2006127477A2 (en) 2005-05-20 2006-05-19 Compositions and methods for treating malaria with cupredoxin and cytochrome

Publications (1)

Publication Number Publication Date
NO20076390L true NO20076390L (en) 2008-02-15

Family

ID=37452644

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076390A NO20076390L (en) 2005-05-20 2007-12-11 Compositions and methods for the treatment of malaria with cupredoxin and cytochrome

Country Status (10)

Country Link
EP (1) EP1882039A4 (en)
JP (1) JP2009504567A (en)
KR (1) KR20080019615A (en)
AU (2) AU2006251742A1 (en)
BR (1) BRPI0612456A2 (en)
CA (1) CA2607739A1 (en)
IL (1) IL187161A0 (en)
MX (1) MX2007014597A (en)
NO (1) NO20076390L (en)
WO (1) WO2006127477A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
CA2608398A1 (en) * 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
JP2009502797A (en) * 2005-07-19 2009-01-29 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ Compositions and methods for controlling angiogenesis with cupredoxins
EP1904642A4 (en) 2005-07-19 2008-11-26 Univ Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
WO2002070542A2 (en) * 2001-03-02 2002-09-12 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Band 3 antigenic peptides, malaria polypeptides and uses thereof

Also Published As

Publication number Publication date
KR20080019615A (en) 2008-03-04
MX2007014597A (en) 2008-01-21
CA2607739A1 (en) 2006-11-30
IL187161A0 (en) 2008-02-09
AU2006251742A1 (en) 2006-11-30
EP1882039A4 (en) 2008-08-20
WO2006127477A3 (en) 2007-03-08
JP2009504567A (en) 2009-02-05
WO2006127477A2 (en) 2006-11-30
EP1882039A2 (en) 2008-01-30
AU2010201360A1 (en) 2010-04-29
BRPI0612456A2 (en) 2009-02-17

Similar Documents

Publication Publication Date Title
EA200970446A1 (en) CONNECTING WITH ALBUMIN MOLECULES AND THEIR APPLICATION
CY1112848T1 (en) SUSPENSION VIRUS INHIBITIONS C
CY1115690T1 (en) ARTHROSPIRA BASED COMPOSITIONS AND THEIR USES
MA30063B1 (en) PYRIMIDINYL-ARYLUREE DERIVATIVES COMPRISING INHIBITORS OF FIBROBLAST GROWTH FACTORS (FCG)
CN108026146A (en) Stable antimicrobial peptide
EA201391519A1 (en) 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF THEIR USE FOR THE TREATMENT OF VIRAL DISEASES
EA201001508A1 (en) BRIDGES HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS
BRPI0517567A (en) compound or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, pharmaceutical composition, uses of a compound or a pharmaceutically acceptable salt, solvate, or derivative thereof and a pharmaceutical composition, and process for preparing a compound
MA33806B1 (en) INHIBITORS OF HEPATITIS C VIRUS
EA200971074A1 (en) ANTI-VIRUS CONNECTIONS
WO2006037073A3 (en) Methods and devices for tissue grasping and assessment
NO20061479L (en) Use of modified cyclosporins for the treatment of HCV disorders
Langleben et al. STRIDE 1: effects of the selective ETA receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials
NO20090598L (en) 6,9-disubstituted purine derivatives and their use in the treatment of skin
EA201001273A1 (en) HEPATITIS C VIRUS INHIBITORS
TW200718358A (en) Control of parasites in animals by N-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and N-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives
NO20063716L (en) Use of low dose erythropoietin in stimulation of endothelial progenitor cells, organ regeneration and slowing of progression of end-organ damage
WO2009152147A3 (en) Compositions and methods for dengue virus (dv) treatment and vaccination
EA201000277A1 (en) CONNECTIONS FOR THE TREATMENT OF HEPATITIS C
EA201001668A1 (en) INHIBITOR PROTEIN ACTIVATING 5-LIPOXYGENASE
NO20076390L (en) Compositions and methods for the treatment of malaria with cupredoxin and cytochrome
BRPI0519355A2 (en) compounds for treatment against flaviviridae
MXPA05012392A (en) Anxiety treatments with ziprasidone.
WO2009005040A1 (en) Pseudomonas aeruginosa outer membrane protein pa4710
WO2006085979A3 (en) Soluble forms of hendra and nipah virus g glycoprotein

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application